LAKE FOREST, Calif., April 7, 2008 (PRIME NEWSWIRE) -- Apria Healthcare Group Inc. (NYSE:AHG) today announced the appointment of Daniel E. Greenleaf to lead its Coram Specialty Infusion Services division as President, replacing John Arlotta, who, as previously announced during Apria's December 2007 acquisition of Coram, Inc., is scheduled to depart the organization in June 2008. Mr. Greenleaf will be based in the Coram division office located in Denver, Colorado.
Mr. Greenleaf most recently served as President and Chief Executive Officer of VioQuest Pharmaceuticals, Inc., a New Jersey-based biopharmaceutical company focused on the acquisition, development and commercialization of oncology drug therapies, from 2005 to 2007.
"We are very pleased to welcome Dan to lead our Coram Specialty Infusion Services division," said Lawrence M. Higby, Chief Executive Officer of Apria Healthcare. "He has over 15 years of relevant experience in senior leadership positions in the healthcare industry. With over 200 infusion or injectable drugs in manufacturers' pipelines currently, Dan's work with pharmaceutical companies known for innovation and growth will further reinforce Coram's position in the marketplace and with manufacturers who seek a strong research partner to conduct early-stage clinical trials. As we continue integrating the Coram and Apria infusion businesses into a single operating unit, Dan's strong executive skills, sales and operations background will be critical attributes as we implement new growth strategies this year and beyond."
Prior to his role at VioQuest Pharmaceuticals, Inc., Mr. Greenleaf was President of U.S. Operations for Celltech Biopharmaceuticals, a NYSE listed company prior to its sale to UCB in 2004. Celltech is a global biopharmaceutical leader focused on severe diseases such as central nervous system disorders, rheumatoid arthritis, Crohn's disease and multiple sclerosis. Additional experience includes serving as Senior Vice President of Operations for Nabi Pharmaceuticals, a research company focused on the development of products targeting nicotine addiction and serious infections, as well as progressively more responsible management and executive-level positions with Schering-Plough Corporation, a global healthcare company, from 1992 to 2002.
"I would like to thank John Arlotta for his leadership during the early months of the Coram acquisition," Mr. Higby said. "His professionalism, leadership and commitment to the business is unwavering and enabled us to meet the objectives we established for the first 100 days after the transaction closed. He and Dan will work closely together in the next 60 days to ensure a smooth handoff of executive responsibilities for the Coram division."
Mr. Greenleaf is a 1987 graduate of Denison University with a Bachelor of Arts (BA) degree in Economics. He also obtained his Masters of Business Administration (MBA) degree in Health Administration from the University of Miami in 1997. Mr. Greenleaf was a captain and navigator in the United States Air Force and served in Operation Desert Storm.
Apria provides home infusion therapy, home respiratory therapy and home medical equipment through approximately 550 locations serving patients in all 50 states. With over $1.6 billion in annual net revenues ($2.1 billion if Coram were included for the full year), Apria continues to be the nation's leading home healthcare company. For more information, visit www.apria.com or www.coramhc.com.
This release may contain statements regarding anticipated future developments that are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Results may differ materially as a result of the risk factors included in the Company's filings with the Securities and Exchange Commission and other factors over which the Company has no control.